Why the study?
Understanding of the interplay between the interferon signaling pathway and SARS-CoV-2 infection has dramatically increased since the start of the pandemic, warranting a review of innate immune signaling pathways and viral counter-defenses.
Key points are not available for this paper at this time.
Design
Review
Informs potential therapeutic targets in innate immunity; leaves open clinical efficacy of interferon modulation in SARS-CoV-2.
Compared to what we knew at the start of the SARS-CoV-2 global pandemic, our understanding of the interplay between the interferon signaling pathway and SARS-CoV-2 infection has dramatically increased. Innate antiviral strategies range from the direct inhibition of viral components to reprograming the host's own metabolic pathways to block viral infection. SARS-CoV-2 has also evolved to exploit diverse tactics to overcome immune barriers and successfully infect host cells. Herein, we review the current knowledge of the innate immune signaling pathways triggered by SARS-CoV-2 with a focus on the type I interferon response, as well as the mechanisms by which SARS-CoV-2 impairs those defenses.
No takes yet. Share an insight, caveat, or question.
Aliyari et al. (2022) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: